Vallon Pharmaceuticals to Present at the Q2 Virtual Investor Summit
07 May 2021 - 10:05PM
Vallon Pharmaceuticals Inc. (NASDAQ: VLON), (“Vallon” or the
“Company”), a clinical-stage biopharmaceutical company primarily
focused on the development of novel drugs that are designed to
deter abuse in the treatment of CNS disorders, announced today that
David Baker, President & Chief Executive Officer of Vallon will
present at the Q2 Virtual Investor Summit on Tuesday, May 18th at
4:15 PM ET.
In addition to the presentation, management will
be available to participate in virtual one-on-one meetings with
qualified members of the investor community who are registered to
attend the conference. For more information about the conference,
please visit the conference website.
A live video webcast of the presentation will be
accessible on the Events page in the Investors section of the
Company’s website (www.vallon-pharma.com) and will be archived for
90 days following the event.
About Vallon
Pharmaceuticals Inc.
Vallon Pharmaceuticals Inc. is a clinical-stage
biopharmaceutical company, headquartered in Philadelphia, PA. The
Company is focused on the development of new medications to help
patients with central nervous system (CNS) disorders. The Company’s
lead investigational product candidate, ADAIR, is a novel abuse
deterrent formulation of amphetamine immediate release being
developed for the treatment of ADHD and narcolepsy.
For more information about the company, please
visit www.vallon-pharma.com.
References and links to websites have been
provided for convenience, and the information contained on any such
website is not a part of, or incorporated by reference into, this
press release. Vallon is not responsible for the contents of
third-party websites.
Investor
Contact:
JTC Team, LLCJenene Thomas(833) 475-8247vallon@jtcir.com
Vallon Pharmaceuticals (NASDAQ:VLON)
Historical Stock Chart
From Apr 2024 to May 2024
Vallon Pharmaceuticals (NASDAQ:VLON)
Historical Stock Chart
From May 2023 to May 2024